BTTX (Better Therapeutics) Total Receivables: $0.00 Mil (As of Sep. 2023)


What is Better Therapeutics Total Receivables?

Better Therapeutics BTTX Total Receivables is $0.00 Mil as of Sep. 2023.

Better Therapeutics's Total Receivables for the quarter that ended in Sep. 2023 was $0.00 Mil.

Better Therapeutics Total Receivables Related Terms

Better Therapeutics Total Receivables Historical Data

* Premium members only.

The historical data trend for Better Therapeutics's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Better Therapeutics Total Receivables Chart

Better Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22
Total Receivables
0.00 0.00 0.00 0.00

Better Therapeutics Quarterly Data
Dec19 Jun20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Better Therapeutics Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of $0.00 Mil mean?
Better Therapeutics (BTTX) has a Total Receivables of $0.00 Mil as of Sep. 2023. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Better Therapeutics and its competitors.
Is Better Therapeutics' Total Receivables too high?
Better Therapeutics' current Total Receivables is $0.00 Mil.
How does Better Therapeutics' Total Receivables compare to CYCN and CELZ?
Better Therapeutics' Total Receivables of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Biotechnology company?
A good Total Receivables depends on the Biotechnology industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Better Therapeutics and its competitors. Better Therapeutics's current Total Receivables is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Better Therapeutics stock overvalued right now?
Better Therapeutics (BTTX) has a current Total Receivables of $0.00 Mil. The current Total Receivables is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For Better Therapeutics (BTTX), the current Total Receivables is $0.00 Mil as of Sep. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Better Therapeutics Business Description

Address 548 Market Street, Suite 49404, San Francisco, CA, USA, 94104
Better Therapeutics Inc is a prescription digital therapeutics company developing a novel form of cognitive behavioural therapy to address the root causes of cardiometabolic diseases. The company has developed a proprietary platform for the development of FDA-regulated, software-based solutions for type 2 diabetes, heart disease and other conditions.